Tearsheet

Kairos Pharma (KAPA)

Market Price (12/5/2025): $0.95 | Market Cap: $16.4 Mil
Sector: Health Care | Industry: Biotechnology

Kairos Pharma (KAPA)

Market Price (12/5/2025): $0.95
Market Cap: $16.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%	Penny stock Mkt Price is 0.9
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
2		Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -4.6 Mil
3		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43%
4		High stock price volatility Vol 12M is 179%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%
1	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
2	Penny stock Mkt Price is 0.9
3	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -4.6 Mil
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43%
6	High stock price volatility Vol 12M is 179%

Valuation, Metrics & Events

	12/5/25	2024	2023	2022	2021
Share Price CYE	$0.95	$1.52
Market Cap CYE ($ Mil)	16.4	20.3	-	-	-
Total Debt ($ Mil)	0.0	0.0	0.6	0.6	0.4
Total Cash ($ Mil)	3.0	1.3	0.1	0.4	0.1
Enterprise Value ($ Mil)	13.3	20.3
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0	0.0
P/EBIT TTM	-2.8	-7.2	0.0	0.0	0.0
P/E TTM	-2.7	-6.6	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9	4.4	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.2	-2.6
P/E TTM (Sector)	-1.6	-1.5	-1.5	-1.3	-2.8

	12/5/25	2024	2023
Share Price CYE	$0.95	$1.52
Market Cap CYE ($ Mil)	16.4	20.3	-
Total Debt ($ Mil)	0.0	0.0	0.6
Total Cash ($ Mil)	3.0	1.3	0.1
Enterprise Value ($ Mil)	13.3	20.3
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	-2.8	-7.2	0.0
P/E TTM	-2.7	-6.6	0.0
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.6	-1.5	-1.5

null

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Drug Candidates in Pipeline	7	4162025	Link
Number of Clinical Programs in Progress	3	10232025	Link
Target Patient Enrollment for ENV-105 Phase 2 Prostate Cancer Trial	100	11042025	Link
Patent Portfolio Validity	Valid until 2040	4162025	Link
Strategic Partnerships	1 (Cedars-Sinai Medical Center)	10232025	Link

Recent
11/14/2025	Earnings Release	Rev: - EPS: -

KAPA Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

1. Continued Net Losses Despite Clinical Progress

Kairos Pharma reported a net loss of -$5.06 million for the trailing 12 months ending September 30, 2025, with no revenue, indicating continued unprofitability for the clinical-stage company. While the company's Q3 2025 earnings per share beat analyst estimates, the overall financial picture of sustained losses can temper investor enthusiasm, especially after initial positive news. 2. Profit-Taking After Initial Stock Surge

Prior to September 2025, Kairos Pharma's stock experienced a significant surge, gaining nearly 79% in the six months leading up to the positive interim efficacy results from its Phase 2 trial of ENV105. This substantial run-up likely led to profit-taking by investors, contributing to a subsequent correction in the stock price. 3. Extended Timeline to Commercialization and Revenue Generation

As a clinical-stage biopharmaceutical company, Kairos Pharma is not yet generating revenue, and the commercialization of its lead drug candidate, ENV105, is still in future development phases. The extended timeline to market and profitability can lead to investor caution and pressure on the stock, particularly after the initial excitement of positive clinical trial data has subsided. 4. Bearish Technical Trading Signals

Technical analysis as of early December 2025 indicated a bearish outlook for Kairos Pharma in the mid-term, with a greater number of sell signals than buy signals. The stock price also declined in four of the last ten trading days leading up to December 4, 2025. 5. Potential for Future Share Dilution

Given the company's ongoing operational costs and lack of revenue, there remains an inherent expectation of future financing needs to fund its clinical trials and development programs. Such financing typically involves the issuance of new shares, which can lead to dilution for existing shareholders and exert downward pressure on the stock price.

Stock Movement Drivers

Fundamental Drivers

The -41.3% change in KAPA stock from 9/4/2025 to 12/4/2025 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).

	9042025	12042025	Change
Stock Price ($)	1.55	0.91	-41.34%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	17.21	17.21	0.00%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

9/4/2025 to 12/4/2025

	Return	Correlation
KAPA	-41.3%
Market (SPY)	5.4%	37.0%
Sector (XLV)	12.0%	10.1%

Fundamental Drivers

The 81.0% change in KAPA stock from 6/5/2025 to 12/4/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

	6052025	12042025	Change
Stock Price ($)	0.50	0.91	80.96%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	15.88	17.21	-8.43%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

6/5/2025 to 12/4/2025

	Return	Correlation
KAPA	81.0%
Market (SPY)	15.7%	13.4%
Sector (XLV)	16.2%	-8.8%

Fundamental Drivers

The -39.4% change in KAPA stock from 12/4/2024 to 12/4/2025 was primarily driven by a -57.8% change in the company's Shares Outstanding (Mil).

	12042024	12042025	Change
Stock Price ($)	1.50	0.91	-39.38%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	10.91	17.21	-57.77%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2024 to 12/4/2025

	Return	Correlation
KAPA	-39.4%
Market (SPY)	13.7%	4.5%
Sector (XLV)	6.3%	2.3%

Fundamental Drivers

null
null

Market Drivers

12/5/2023 to 12/4/2025

	Return	Correlation
KAPA
Market (SPY)	53.3%	5.5%
Sector (XLV)	20.1%	2.9%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
KAPA Return	-	-	-	-	-	-40%	-40%
Peers Return	2%	-1%	6%	8%	-0%	3%	18%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	112%
Monthly Win Rates [3]
KAPA Win Rate	-	-	-	-	33%	30%
Peers Win Rate	13%	8%	13%	12%	10%	90%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
KAPA Max Drawdown	-	-	-	-	-	-70%
Peers Max Drawdown	-2%	-5%	0%	-0%	-1%	-2%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, AIXC, ALPS, BBOT, EVMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)

How Low Can It Go

KAPA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Kairos Pharma (KAPA)

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. “Checkpoints” refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution. The human immune system can tell the difference between normal cells in the body and those it sees as “foreign,” which allows it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses checkpoints. Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system. We are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing an activated T cell therapy that is designed to transform a patient’s T cells into killer activated T cells against cancerous stem cells. These activated T cells are induced to target several antigen targets on glioblastoma cancer stem cells, the initiators and propagators of glioblastoma tumors. In June 2021, Kairos acquired Enviro Therapeutics, Inc., a California corporation (“Enviro”), through a share exchange. Enviro’s shareholders exchanged 100% of the outstanding shares of Enviro for 6,000,000 shares of newly issued restricted shares of common stock of Kairos. After the closing, Enviro became a wholly owned subsidiary of Kairos. The acquisition allowed us to incorporate into our company Enviro’s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Our drug candidate portfolio currently consists of a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics. Our pipeline is summarized below: . Five pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response, including KROS 101, 102, 201, 301, and 401, which are designed to reverse immunosuppression of T cells that is caused by cancer. - KROS 101 and 102 are small molecules that are agonist and antagonist for the GITR (glucocorticoid induced TNF-like receptor) ligand, which respectively promote and inhibit T cell growth and function. GITR is a checkpoint central to control the numbers of T cells of the immune system. These molecules are in the preclinical stage and are being developed for clinical trials. - KROS 201 is an autologous T cell therapy targeting cancer stem cells of glioblastoma. This therapy has received an IND from the FDA for clinical trial and is undergoing preparation for a Phase 1 clinical trial for patients with recurrent glioblastoma. - KROS 301 is a small molecule that targets the NF-ĸß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer. This molecule is in preclinical testing. - KROS 401 is a cyclic peptide which inhibits the IL-4 and IL-13 (cytokines that play a critical role in the suppression of T cells by macrophages at the site of the tumor) receptor and is designed to reverse the immunosuppression induced by macrophages in the tumor microenvironment. . Two therapeutic agents developed by our Enviro subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. - ENV 105 is an antibody that targets CD105 / Endoglin which is expressed in tumor cells and surrounding cells as the tumor becomes resistant to therapeutics in prostate cancer and lung cancer. This therapy is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial in lung cancer, both of which began enrolling patients in September 2023. ENV 105 has received an IND from the FDA. - ENV 205 is an antibody that targets mitochondrial DNA which is elevated as patients become resistant to chemotherapies. This therapy is in preclinical testing. As of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator. Kairos Pharma, Ltd. was originally incorporated on June 17, 2013 under the laws of the State of California as NanoGB13, Inc. We changed our name to “Kairos Pharma, Ltd.” on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State of the State of California and, on the same date, we also filed with the Secretary of State of the State of Delaware a certificate of conversion from a non-Delaware corporation to a Delaware corporation pursuant to the Delaware General Corporation Law. In addition, on May 10, 2023, we also filed a certificate of incorporation with the Secretary of State of the State of Delaware and became a Delaware corporation. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Kairos Pharma (symbol: KAPA) is a fictional company often used in case studies or educational materials and therefore does not have actual major products or services.

AI Generated Analysis | Feedback

As a public pharmaceutical company, Kairos Pharma (KAPA) would primarily sell its products to other companies rather than directly to individual consumers. The major customers for a pharmaceutical manufacturer are typically the large pharmaceutical wholesale distributors, which then supply drugs to pharmacies, hospitals, and other healthcare providers.

Based on the standard business model for a pharmaceutical company operating in major markets, Kairos Pharma's major customers would include:

McKesson Corporation (MCK)
AmerisourceBergen Corporation (ABC)
Cardinal Health, Inc. (CAH)

These three companies are the largest pharmaceutical distributors in the United States and typically account for a significant portion of a pharmaceutical manufacturer's sales revenue, acting as the crucial intermediary in the drug supply chain.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

John S. Yu, Chief Executive Officer & Chairman
Dr. John S. Yu founded Kairos Pharma on June 17, 2013. He is an accomplished neurosurgeon and immunotherapy expert, holding a BAS from Stanford, and an MD from Harvard Medical School and MIT. Dr. Yu also serves as a Professor of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center. He has developed numerous investigational drugs with the FDA (8 new drugs mentioned) and led multiple clinical trials. Prior to Kairos Pharma, he was the CEO and Chairman of AcTcell, and a Director of Enviro Therapeutics. His career has focused on groundbreaking research in cancer therapeutics, and he holds numerous patents for immunotherapies and nanotechnologies from his NIH-funded laboratory.

Doug Samuelson, Chief Financial Officer
Doug Samuelson brings over 25 years of experience in finance, having served as CFO for various biopharma companies. He is a CPA in the State of California. His previous roles include CFO of Wellness Center USA, CFO of AdvaVet, Inc., CFO of Solis Tek, Inc., and Director of Accounting of Second Sight Medical Products, Inc. His expertise encompasses financial management and regulatory compliance.

Neil Bhowmick, Chief Scientific Officer & President, Enviro Therapeutics
Dr. Neil Bhowmick possesses over 20 years of extensive biochemistry expertise. He has filed and prosecuted patents for therapeutics and devices, authored 110 peer-reviewed publications, and led foundational and preclinical cancer research. He holds 6 patents for biomarker detection platforms and stromal targeted therapeutics, including ENV105 and ENV205. Dr. Bhowmick's background includes a fellowship at Vanderbilt University Medical Center and serving as Research Director at Oppenheimer Urologic Reference Laboratory (OURLab). He has also been a consultant at Xencor Inc. and Tracon Pharma.

Ramchandran Murali, VP, Research and Development
Dr. Ramchandran Murali is an immunologist and molecular engineer recognized for his work in developing pharmacological agents to counter immune suppression in cancer. His extensive research background is instrumental in advancing Kairos Pharma's innovative drug pipeline. He is also a Professor of Biomedical Sciences and Research in Immunology at Penn/Cedars-Sinai Medical Center, and a leading expert in X-ray crystallography, biophysical, biochemical, and immunology fields, having made significant advances in molecular engineering and cell surface receptors. He has developed numerous technologies that reverse key mechanisms of immune suppression of cancer.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Kairos Pharma (KAPA) is a clinical-stage biopharmaceutical company focusing on oncology therapeutics. The addressable markets for their main product candidates are as follows:

ENV105 (Castrate-Resistant Prostate Cancer): The global castrate-resistant prostate cancer (CRPC) market was estimated at approximately USD 12.95 billion in 2024 and is projected to reach about USD 21.44 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.7% from 2025 to 2030. The metastatic CRPC therapeutics market specifically was valued at USD 16.46 billion in 2024 and is projected to grow to USD 87.19 billion by 2032 with a CAGR of 22.5% during the forecast period.
ENV105 (Lung Cancer): The global lung cancer therapeutics market size was approximately USD 35.37 billion in 2025 and is forecasted to reach around USD 71.30 billion by 2034, exhibiting a CAGR of 8.10% from 2025 to 2034. Another estimate places the global lung cancer market at USD 38.4 billion in 2025, growing to USD 95.1 billion in 2034 with a CAGR of 10.6%.
KROS201 (Glioblastoma): The global glioblastoma treatment market was valued at USD 3.05 billion in 2024 and is expected to reach USD 6.22 billion by 2032, at a CAGR of 9.30% during the forecast period. Other projections estimate the global glioblastoma multiforme treatment market to grow from USD 3.72 billion in 2024 to USD 7.87 billion by 2033 with a CAGR of 8.68%.
KROS401 (Triple Negative Breast Cancer): The global triple negative breast cancer (TNBC) market was valued at USD 1.06 billion in 2024 and is expected to reach USD 1.63 billion by 2032, growing at a CAGR of 5.50% from 2025 to 2032. Another report indicates the global TNBC market size to be USD 1.15 billion in 2025, projected to reach USD 1.41 billion by 2029 with a CAGR of 5.1%.
KROS101, KROS102, KROS301: Specific addressable market sizes for these individual product candidates beyond the general oncology or immunotherapy market are not available. However, the broader global cancer immunotherapy market was valued at USD 226.38 billion in 2024 and is projected to reach USD 443.17 billion by 2030, growing at a CAGR of 11.90%. The global immunotherapy drugs market, which encompasses these types of therapies, was estimated at USD 257.6 billion in 2024 and is projected to reach USD 486.36 billion by 2030, growing at a CAGR of 11.2%.

AI Generated Analysis | Feedback

Expected Drivers of Future Revenue Growth for Kairos Pharma (KAPA)

Over the next 2-3 years, Kairos Pharma's potential for revenue growth is primarily linked to the successful advancement and commercialization of its clinical-stage pipeline. The key expected drivers include:

Advancement and Commercialization of ENV105: Kairos Pharma's lead therapeutic candidate, ENV105, an antibody targeting CD105, is currently undergoing Phase 2 clinical trials for advanced metastatic prostate cancer and Phase 1 trials for lung cancer. The company has reported positive interim safety and efficacy results from the Phase 2 prostate cancer trial. Successful progression through clinical development, regulatory approval, and subsequent market launch of ENV105 would be a significant driver of future product revenue.
Development and Launch of KROS101: The company has presented promising new data on KROS101, an investigational small molecule GITR ligand agonist, as a potential cancer immunotherapy. If KROS101 successfully navigates clinical trials and gains regulatory approval, its commercialization would introduce a new product and revenue stream for Kairos Pharma.
Expansion into New Cancer Indications: Kairos Pharma's strategy involves leveraging its lead candidate, ENV105, to address multiple cancer types by reversing drug resistance and restoring the effectiveness of standard therapies. Successful clinical trials and subsequent approvals for additional cancer indications beyond prostate and lung cancer would expand the addressable market and contribute to revenue growth.
Strategic Partnerships and Collaborations: Recent partnerships are anticipated to enhance Kairos Pharma's innovation in pharmaceutical products and bolster its research and development capabilities. These collaborations could generate revenue through various mechanisms, such as upfront payments, milestone payments tied to development progress, and royalty streams from licensed assets.

AI Generated Analysis | Feedback

Share Issuance

On September 16, 2024, Kairos Pharma completed its Initial Public Offering (IPO), issuing 1.55 million common shares at an offering price of $4.00 per share, raising gross proceeds of $6.2 million.
In January 2025, the company raised an additional $3.5 million through a Private Investment in Public Equity (PIPE) transaction by selling 2.5 million common units at $1.40 each, along with warrants.
The total number of shares outstanding for Kairos Pharma increased by 35.56% in one year.

Inbound Investments

The company's Phase 2 clinical trial for ENV105 in prostate cancer is partially funded by a $3.2 million NIH grant.
Kairos Pharma raised $3.5 million in January 2025 via a Private Investment in Public Equity (PIPE) transaction from accredited investors.
In November 2025, Kairos Pharma received a Department of Defense grant to support the study of its lead candidate ENV105 for preventing drug resistance in lung cancer, and another grant for research of ENV205 to treat chemotherapy drug resistance and cachexia.

Capital Expenditures

Proceeds from the IPO and subsequent financings are primarily allocated to advancing clinical trials, including Phase 1 and 2 trials for its lead candidate ENV-105 in lung and prostate cancer.
The company's operational expenses, largely driven by research and development as a clinical-stage biopharmaceutical company, are projected to be $3.7 million for 2025 and $7.2 million for 2026.
Kairos Pharma reported a quarterly burn rate of approximately $0.6 million.

Better Bets than Kairos Pharma (KAPA)

	KAPA	Better Performance than KAPA
Metric	Value	INDUSTRY: Biotechnology
Total Yield	-38.6%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), VRTX (3.7%), ABBV (3.4%)
P/Op Inc	-2.7

	KAPA	Better Performance than KAPA
Metric	Value	SECTOR: Health Care
Total Yield	-38.6%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/Op Inc	-2.7

	KAPA	Better Performance than KAPA
Metric	Value	ALL OTHER SECTORS
Total Yield	-38.6%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/Op Inc	-2.7

		Best Bets In Health Care Sector
	KAPA	RPRX	HALO	DOCS	UTHR	CPRX	HRMY	LGND	ISRG	GMED	MD
What You Pay
P/E	-2.6	19.9	14.4	54.3	14.4	11.1	8.5	71.4	58.1	18.2	8.7
P/EBIT	-2.7	9.6	11.3	55.6	10.9	9.3	6.5	51.9	56.6	17.8	5.9
What You Get
Rev Chg Q	�	7.9%	22.1%	23.2%	6.8%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%
Rev Chg LTM	�	3.7%	31.2%	20.2%	13.5%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%
Rev Chg 3Y Avg	�	1.5%	29.0%	17.4%	19.0%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%
FCF/Rev 3Y Avg	�	115.2%	45.0%	42.7%	34.3%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Day 8 of Gains Streak for Kairos Pharma Stock with 67% Return (vs. 30% YTD) [9/9/2025]	Notification

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to KAPA. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
LXP	LXP Industrial Trust	2.8	406.1%	25.7%
OLMA	Olema Pharmaceuticals	2.4	237.1%	374.1%
COGT	Cogent Biosciences	5.4	178.2%	404.0%
CDTX	Cidara Therapeutics	5.9	119.6%	720.3%
SGML	Sigma Lithium	1.1	113.2%	-11.1%
IRWD	Ironwood Pharmaceuticals	0.6	99.5%	-15.8%
ALMS	Alumis	0.6	82.4%	5.6%
NPCE	NeuroPace	0.6	80.5%	51.7%
BW	Babcock & Wilcox Enterprises	0.7	80.5%	311.6%
CBLL	CeriBell	0.7	75.4%	-26.0%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CCOI	Cogent Communications	0.9	-53.0%	-74.0%
UP	Wheels Up Experience	0.5	-48.0%	-60.0%
TLRY	Tilray Brands	7.7	-41.8%	-45.7%
AMSC	American Superconductor	1.4	-41.4%	34.0%
CTEV	Claritev	0.6	-41.2%
BTDR	Bitdeer Technologies	2.5	-40.7%	-41.6%
FRMI	Fermi	11.1	-40.2%
JANX	Janux Therapeutics	1.0	-39.3%	-69.4%
ARDT	Ardent Health	1.2	-39.1%	-48.1%
SMR	NuScale Power	3.4	-35.9%	27.4%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

Peer Comparisons for Kairos Pharma

Peers to compare with:

Financials

	KAPA	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Kairos P.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Price	0.91	457.36	2.63	1.17	11.54	21.93	7.08
Mkt Cap	0.0	116.9	-	-	-	-	58.5
Rev LTM	0	11,723	0	-	0	10	0
Op Inc LTM	-5	-92	-5	-	-93	-70	-70
FCF LTM	-5	3,337	-6	-	-60	-64	-6
FCF 3Y Avg	-2	2,064	-10	-	-	-	-2
CFO LTM	-5	3,718	-6	-	-60	-64	-6
CFO 3Y Avg	-2	2,419	-10	-	-	-	-2

Growth & Margins

	KAPA	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Kairos P.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Rev Chg LTM	-	10.3%	-	-	-	-	10.3%
Rev Chg 3Y Avg	-	10.5%	-	-	-	-	10.5%
Rev Chg Q	-	11.0%	-	-	-	-	11.0%
QoQ Delta Rev Chg LTM	-	2.7%	-	-	-	-	2.7%
Op Mgn LTM	-	-0.8%	-	-	-	-700.7%	-350.7%
Op Mgn 3Y Avg	-	26.2%	-	-	-	-	26.2%
QoQ Delta Op Mgn LTM	-	1.0%	-	-	-	-	1.0%
CFO/Rev LTM	-	31.7%	-	-	-	-635.6%	-302.0%
CFO/Rev 3Y Avg	-	23.1%	-	-	-	-	23.1%
FCF/Rev LTM	-	28.5%	-	-	-	-636.5%	-304.0%
FCF/Rev 3Y Avg	-	19.8%	-	-	-	-	19.8%

Valuation

	KAPA	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Kairos P.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Cap	0.0	116.9	-	-	-	-	58.5
P/S	-	8.5	-	-	-	-	8.5
P/EBIT	-2.7	22.4	-	-	-	-	9.9
P/E	-2.6	27.2	-	-	-	-	12.3
P/CFO	-2.3	26.9	-	-	-	-	12.3
Total Yield	-38.6%	3.7%	-	-	-	-	-17.5%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.3%	-	-	-	-	2.3%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.2	-0.0	-	-	-	-	-0.1

Returns

	KAPA	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Kairos P.	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
1M Rtn	4.8%	8.5%	-	23.2%	-4.6%	-	6.6%
3M Rtn	-41.3%	15.2%	-	-	14.5%	-	14.5%
6M Rtn	81.0%	3.1%	-	-	-	-	42.0%
12M Rtn	-39.4%	-1.4%	-	-	-	-	-20.4%
3Y Rtn	-	44.0%	-	-	-	-	44.0%
1M Excs Rtn	3.6%	7.2%	-	22.0%	-5.9%	-	5.4%
3M Excs Rtn	-52.9%	9.7%	-	-	10.8%	-	9.7%
6M Excs Rtn	65.5%	-12.4%	-	-	-	-	26.5%
12M Excs Rtn	-54.0%	-15.2%	-	-	-	-	-34.6%
3Y Excs Rtn	-	-28.7%	-	-	-	-	-28.7%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	8/12/2025	4/15/2025	9/17/2024	2/14/2024	3/29/2023	3/29/2023
Key Financials
Total Revenue	0	0	0	0	0	0
EBITDA	-4	-2	-2	-0	-2	-1
Operating Income	-5	-2	-2	-1	-2	-1
Net Income	-5	-3	-2	-1	-2	-1
EPS	-0.34	-0.23	-0.16	-0.10	-0.10	-0.09
Growth Rates
Total Revenue Growth	-	-	-	-	-	-
EBITDA Growth	-156.5%	-45.0%	-260.6%	77.1%	-80.0%	-
Operating Income Growth	-141.4%	-36.7%	-200.2%	70.6%	-85.8%	-
Net Income Growth	-134.8%	-43.7%	-72.6%	51.0%	-104.0%	-
Margins
EBITDA Margin	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-
Cash & Debt
Total Cash	3	1	0	0	0	0
Total Debt	0	0	1	1	0	0
Net Debt / (Cash)	-3	-1	1	0	0	0
Cash Flows
Net Cash from Operations	-5	-4	0	-0	-0	-0
Free Cash from Operations	-5	-4	0	-0	-0	-0
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/12/2025	5/14/2025	4/15/2025	11/14/2024	9/17/2024	5/13/2024	9/17/2024	2/14/2024	9/29/2023	9/18/2023	2/14/2024	2/14/2024
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-1	-1	-1	-1	-0	-0	-1	-0	-0	-0	-0	-0
Operating Income	-1	-1	-1	-0	-0	-0	-1	-0	-0	-0	-0	-0
Net Income	-1	-1	-1	-1	-0	-0	-1	-0	-0	-0	-0	-0
EPS	-0.08	-0.08	-0.08	-0.10	-0.02	-0.03	-0.10	-0.03	-0.02	-0.01	-0.02	-0.02
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	0	0	0	-
Ebitda TTM	-4	-3	-2	-2	-2	-2	-2	-1	-0	-0	-0	-
Operating Income TTM	-5	-3	-2	-2	-2	-2	-2	-1	-1	-1	-1	-
Net Income TTM	-5	-4	-3	-3	-2	-2	-2	-1	-1	-1	-1	-
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Growth	-659.3%	-394.7%	10.4%	-256.3%	-5.8%	-187.2%	-649.3%	-194.0%	-115.0%	32.3%	-	-
Operating Income Growth	-555.9%	-341.1%	-32.8%	-33.4%	-4.7%	-127.8%	-505.0%	-131.5%	-76.7%	14.3%	-	-
Net Income Growth	-462.1%	-290.7%	12.3%	-235.6%	-7.2%	-121.2%	-470.4%	-33.3%	38.7%	37.9%	-	-
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	3	4	1	3	0	0	0	0	0	0	0	-
Total Debt	0	0	0	0	0	0	1	0	1	1	1	0
Net Debt / (Cash)	-3	-4	-1	-3	-0	-0	1	-0	0	0	0	-
Cash Flows Quarterly
FCF from Operations	-1	-1	-2	-2	-0	0	0	0	-0	-0	-0	-0
Cash Flows TTM
FCF from Operations TTM	-5	-5	-4	-2	0	0	0	-0	-0	-0	-0	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-40.3%	-37.3%	-47.0%	-18.9%	-14.9%	-20.3%	-93.1%	-25.0%	-23.6%	-14.6%	-21.4%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-31.5%	-24.4%	-19.0%	-24.5%	-31.7%	-33.1%	-36.6%	-17.5%	-17.9%	-15.9%	-17.0%	-

Price Behavior

Price Behavior

Market Price	$0.91
Market Cap ($ Bil)	0.0
First Trading Date	09/16/2024
Distance from 52W High	-57.3%
	50 Days	200 Days
DMA Price	$1.01	$1.43
DMA Trend	down	down
Distance from DMA	-9.9%	-36.5%
	3M	1YR
Volatility	101.7%	179.7%
Downside Capture	233.61	5.36
Upside Capture	-81.47	-44.92
Correlation (SPY)	38.0%	4.4%

KAPA Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	4.78	3.99	3.08	1.48	0.40	1.12
Up Beta	7.56	6.45	6.19	3.37	0.13	-0.68
Down Beta	7.09	6.27	6.56	5.72	1.44	-0.89
Up Capture	104%	90%	-68%	-7%	-24%	-3%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	7	17	28	57	103	123
Down Capture	464%	311%	179%	-180%	13%	46%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	13	23	32	64	139	170

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

null

Based On 5-Year Data

null

Based On 10-Year Data

null

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	125,497
Short Interest: % Change Since 10312025	-47.5%
Average Daily Volume	285,701
Days-to-Cover Short Interest	1
Basic Shares Quantity	17,213,017
Short % of Basic Shares	0.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8122025	10-Q 6/30/2025
3312025	5142025	10-Q 3/31/2025
12312024	4152025	10-K 12/31/2024
9302024	11142024	10-Q 9/30/2024
3312024	5132024	S-1/A 3/31/2024
12312023	9172024	424B4 12/31/2023
6302023	9292023	S-1 6/30/2023
3312023	9182023	DRS/A 3/31/2023
12312022	2142024	S-1/A 12/31/2022
12312021	3292023	DRS 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Kairos Pharma (KAPA)

Market Price (12/5/2025): $0.95 | Market Cap: $16.4 MilSector: Health Care | Industry: Biotechnology

Kairos Pharma (KAPA)

Market Price (12/5/2025): $0.95Market Cap: $16.4 MilSector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

KAPA Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Kairos Pharma (KAPA)

Expected Drivers of Future Revenue Growth for Kairos Pharma (KAPA)

Share Issuance

Inbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Kairos Pharma (KAPA)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Kairos Pharma

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/5/2025): $0.95 | Market Cap: $16.4 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (12/5/2025): $0.95
Market Cap: $16.4 Mil
Sector: Health Care
Industry: Biotechnology